Literature DB >> 9081377

Single agent paclitaxel in advanced squamous cell head and neck carcinoma.

V Gebbia, A Testa, G Cannata, N Gebbia.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 9081377     DOI： 10.1016/0959-8049(96)00002-0

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  6 in total

Review 1.  The taxoids. Comparative clinical pharmacology and therapeutic potential.

Authors:  E A Eisenhauer; J B Vermorken
Journal:  Drugs       Date:  1998-01       Impact factor: 9.546

2.  Chemoradiation in Advanced Head and Neck Cancers: A Comparison of two Radiosensitizers, Paclitaxel and Cisplatin.

Authors:  Sohit Paul Kanotra; Sonika Kanotra; Ashutosh Gupta; J Paul
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2011-05-07

3.  Potential biomarkers for paclitaxel sensitivity in hypopharynx cancer cell.

Authors:  Cheng-Zhi Xu; Run-Jie Shi; Dong Chen; Yi-Yuan Sun; Qing-Wei Wu; Tao Wang; Pei-Hua Wang
Journal:  Int J Clin Exp Pathol       Date:  2013-11-15

Review 4.  Systemic therapy in head and neck cancer: changing paradigm.

Authors:  Samit Purohit; Rohan Bhise; D Lokanatha; K Govindbabu
Journal:  Indian J Surg Oncol       Date:  2012-12-01

5.  Phase II trial of biweekly gemcitabine and paclitaxel with recurrent or metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group study S0329.

Authors:  Binu Malhotra; James Moon; Omar Kucuk; Joseph I Clark; Susan G Urba; Gregory T Wolf; Francis P Worden
Journal:  Head Neck       Date:  2014-01-29       Impact factor: 3.147

Review 6.  A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck.

Authors:  C Couteau; N Chouaki; S Leyvraz; D Oulid-Aissa; A Lebecq; C Domenge; V Groult; S Bordessoule; F Janot; M De Forni; J P Armand
Journal:  Br J Cancer       Date:  1999-10       Impact factor: 7.640
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.